Vigabatrin
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
- Vigabatrin
- Vigabatrin: From West Syndrome to ARX-Related X-Linked Intellectual Disability (With or Without Seizures)
Vigabatrin: From West Syndrome to ARX-Related X-Linked Intellectual Disability (With or Without Seizures)
One-Sentence Summary
Vigabatrin is an antiepileptic drug originally used for West syndrome (infantile spasms) and developmental and epileptic encephalopathy. The TxGNN model predicts it may be effective for ARX-related X-linked intellectual disability, with or without seizures, but there are currently no registered clinical trials and only indirect literature (9 publications, mostly reviews and case reports on related genetic epilepsies) supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | West syndrome; developmental and epileptic encephalopathy (from the knowledge graph; no approved indication text is available for the Singapore licence) |
| Predicted New Indication | Intellectual disability, X-linked, with or without seizures, ARX-related |
| TxGNN Prediction Score | 98.66% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. From general pharmacology, vigabatrin irreversibly inhibits GABA transaminase, the enzyme that breaks down GABA, and so raises brain GABA levels.
ARX variants impair the development and migration of GABAergic interneurons. They are a known cause of infantile spasms and early-onset epileptic encephalopathy. Because vigabatrin is already used for infantile spasms (West syndrome), boosting GABA is a plausible way to control the spasms and seizures seen in ARX-related disease.
There are important limits. Vigabatrin would not be expected to correct the underlying intellectual disability. No ARX-specific vigabatrin study was identified. The high TxGNN score is a computational prediction only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
None of the publications is a randomised trial, and none is specific to ARX. They are listed by study type, with reviews and guidelines first.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38409029 | 2024 | Review/Guideline | Orphanet J Rare Dis | Targeted review of treatment guidelines for seizures in Rett syndrome and tuberous sclerosis complex |
| 26494205 | 2016 | Retrospective multicentre survey | Brain Dev | Epilepsy features and antiepileptic drug response in LIS1-associated classic lissencephaly |
| 23400943 | 2013 | Review | Pharmacotherapy | Summary of antiepileptic therapy for seizures in neurogenetic disorders |
| 38703411 | 2024 | Review | Mol Genet Metab | Clinical and molecular review and management guidelines for ALG13-CDG, where epileptic spasms are common |
| 26365141 | 2015 | Review | Curr Pharm Des | GABAergic neurobiology of fragile X spectrum disorder and targeted treatments |
| 32323081 | 2020 | Case report/Review | Neurol Sci | Clinical characterisation of 17p13.3 microdeletion (YWHAE and CRK genes) |
| 35545418 | 2022 | Case report/Review | J Cent South Univ Med Sci | Two NEXMIF-related cases with intellectual disability and epilepsy, with literature review |
| 36436329 | 2023 | Case report | Pediatr Neurol | Partial efficacy of vigabatrin in an infant with West syndrome due to pyruvate dehydrogenase complex deficiency |
| 41004695 | 2025 | Case report | Neurology | Vigabatrin-associated MRI changes with acute hydrocephalus in an infant with LIS1-related lissencephaly |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN07955P | SABRIL TABLET 500 mg | Film-coated tablet | Not available |
Safety Considerations
- Disease associations flagged in the knowledge graph (not label text): kidney disease, pyoureter, congestive heart failure, peripheral nervous system disease, peripheral neuropathy, anaemia, macrocytic anaemia and scotoma (visual field defect). The scotoma flag is consistent with the known retinal and visual field toxicity of vigabatrin, which is a particular concern in young infants.
- Drug interactions: 65 interactions were identified. Major interactions include systemic and other corticosteroids (hydrocortisone, prednisone, prednisolone, dexamethasone, betamethasone, triamcinolone, budesonide), oxyquinoline (topical) and deferoxamine. Moderate interactions include morphine, opium, diphenoxylate, difenoxin, dronabinol, nabilone, metoclopramide, sibutramine and ethanol.
- Case report signal: One case report describes vigabatrin-associated MRI abnormalities with obstructive hydrocephalus in an infant with lissencephaly.
Package insert warnings and contraindications were not available. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is mechanistically plausible for the seizure component, because ARX variants affect GABAergic interneurons and vigabatrin is used in infantile spasms. However, there are no clinical trials, no ARX-specific studies, and the supporting literature is indirect. The evidence remains at the research-question stage. The visual field toxicity concern in infants further argues against moving forward without more data.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA (a blocking gap for safety screening)
- Mechanism of action data confirmed from DrugBank
- ARX-specific clinical data, such as case series or registry data on vigabatrin in ARX-related epilepsy
- A retinal and visual field monitoring plan for infants and young children
- Approved indication text for the Singapore licence, to compare with the predicted use
Other Predicted Indications (Lower Priority)
The other nine predictions have no clinical trials or literature and rest only on the computational score. All are at evidence level L5 with a Hold recommendation.
| Rank | Predicted Indication | TxGNN Score | Comment | |------|------|------|------| | 2 | Episodic kinesigenic dyskinesia | 97.26% | Usually treated with sodium channel blockers; no established GABAergic rationale | | 3 | 1q44 microdeletion syndrome | 96.71% | Seizure control is conceivable but speculative | | 4 | PURA-related neonatal hypotonia-seizures-encephalopathy syndrome | 96.56% | General antiseizure rationale only | | 5 | DK1-CDG | 96.47% | No established link to GABA metabolism | | 6 | Microtriplication 11q24.1 | 96.31% | Mechanistic rationale unclear | | 7 | CCDC115-CDG | 96.27% | No established link to GABA transaminase inhibition | | 8 | Neonatal period electroclinical syndrome | 96.25% | Related to West syndrome, but not a standard vigabatrin use; infant retinal risk applies | | 9 | Genetic lethal multiple congenital anomalies/dysmorphic syndrome | 96.22% | Broad category with no specific mechanism | | 10 | COG2-CDG | 96.20% | No established link to GABAergic pathways |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.